Silence Therapeutics PLC (SLN)
AI stock analysis · as of Jun 25, 2026
Loading microstructure…
Silence Therapeutics is a UK-based clinical-stage siRNA biotech (~$452M market cap) with no product revenue, a thin cash balance ($11M cash, FCF -$62M), and a binary fate tied to divesiran's Phase 2 readout in polycythemia vera (Q3 2026). The core investment question is whether the wholly-owned divesiran program can de-risk into a partnerable/approvable asset before dilution and the loss of major collaborators (AstraZeneca, Hansoh) erode the equity story, while zerlasiran finds a Phase 3 partner.
valuationExpensive on traditional metrics (P/S 538x, P/B 9.1x, negative EV/EBITDA and FCF yield -10%) but valuation here is purely option-value on divesiran and zerlasiran — the only justifiable framework is risk-adjusted NPV of the pipeline, where the street's $29 mean target implies meaningful clinical success probability.
This analysis is from Jun 25, 2026. Want the latest on SLN, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Divesiran Phase 1 PV durability data has driven multiple re-rating events in 2026 (Cantor upgrade, April +19%, June single-day rally), with a high-impact Q3 2026 Phase 2 readout still ahead
- · Zerlasiran targets Lp(a) cardiovascular disease, a market with 20%+ global prevalence and no approved therapy — a successful Phase 3 partnership could mirror prior deal economics (AZ $60M upfront, Hansoh $16M upfront)
- · Stock trades at $9.56 vs analyst mean target of $29.17 (high $75) with 6 analysts at 'buy' — implied ~3x upside if pipeline executes
- · Recovery of full global rights to SLN312 post-AstraZeneca exit gives Silence an additional clinical-stage asset to repartner
- · Platform optionality into obesity (SLN098) and cholesterol (SLN365) — two of the largest commercial pharma markets — provides longer-dated shots on goal
- · Insiders hold 24.4% and institutions 44.5%, indicating meaningful aligned ownership; short interest at 5.8% of float with 9.6 days to cover offers modest squeeze potential on positive data
Bear case
- · Cash position of only $11M against FCF burn of -$62M makes near-term dilution highly likely; ATM facility with Jefferies is already active and management's 'runway into 2028' depends on milestone payments that may not materialize
- · Both major collaborators exited within months: Hansoh (Dec 2024) ended all three targets and AstraZeneca terminated SLN312 (March 2026), eliminating up to $390M in potential milestones
- · Divesiran Phase 2 is placebo-controlled in only 48 patients — limited statistical power makes a failure or ambiguous readout a real risk, and a miss would be existential for the lead program
- · Revenue collapsed from $43.3M (2024) to $0.56M (2025), a -98.7% drop, reflecting the disappearance of collaboration income and leaving net loss at -$88.6M
- · Price-to-sales of 538x and price-to-book of 9.1x reflect a story stock with no fundamental anchor; ROE of -92.6% underscores the cash incineration
- · Zerlasiran is Phase 3-ready but stranded without a partner; intense competition from Alnylam and Arrowhead with deeper pockets and more advanced RNAi platforms limits partnering leverage
Catalysts
- · Divesiran Phase 2 topline readout in PV — guided Q3 2026 / August 2026 (single largest value driver)
- · Next earnings on 2026-08-06 — likely to coincide with or precede pipeline updates and cash guidance refresh
- · Announcement of a zerlasiran Phase 3 partnership — would validate the Lp(a) asset and bring upfront cash
- · New collaboration deals on SLN312 (now wholly owned) or platform expansion programs (SLN098 obesity, SLN365)
- · Short interest of 5.8% float with 9.6 days-to-cover creates a squeeze setup on a positive divesiran readout
- · Any ATM drawdown disclosures or capital raise — likely a negative catalyst given small market cap
Key risks
- · Divesiran Phase 2 failure or ambiguous data — existential for the equity given the small n=48 trial design
- · Dilution risk: $11M cash vs $62M annual burn forces equity issuance well before any commercial revenue
- · Failure to secure a zerlasiran Phase 3 partner leaves a key asset stranded with no path to approval
- · Further collaborator attrition or inability to repartner SLN312 following AZ's exit
- · Competitive displacement by Alnylam, Arrowhead, and other RNAi leaders with better-resourced clinical programs
What to watch
- · Q3 2026 / August 2026 divesiran Phase 2 PV topline readout — the defining event
- · Next earnings 2026-08-06 for cash runway update and any Phase 3 partner commentary on zerlasiran
- · ATM facility usage disclosures and any private placement announcements (dilution signal)
- · Any new licensing or partnership announcement for SLN312 (ANGPTL3) or platform assets
- · Technical levels: 52-week high $9.46 as resistance; 52-week low $4.19 as key support ahead of the binary readout
- · Short interest trajectory — currently 5.8% float, 9.62 days to cover; rising figures into readout could amplify post-data moves
Key metrics
Price target rationale
Base case ($12) assumes modestly positive Phase 1 follow-on data and continued partnering optionality, with some dilution priced in. Bull case ($28) approximates the street mean on a successful Phase 2 divesiran readout enabling NDA path + zerlasiran partner. Bear case ($3.50, below the $4.19 52-week low) reflects a failed/ambiguous Phase 2 readout combined with dilutive ATM issuance — a realistic floor given $11M cash and $62M burn.
On Wall Street's view (mixed): The $29.17 mean target with $4-$75 range reflects extreme binary outcomes typical of clinical-stage biotech; we agree the upside is real if divesiran reads out positively, but the wide dispersion and thin cash position mean the consensus likely under-weights dilution and Phase 2 trial risk.
Latest filing (10-K)
Silence Therapeutics is a cash-burning UK siRNA company with one Phase 2 readout (divesiran in PV, Q3 2026) that will make or break the story, a Phase 3-ready Lp(a) asset needing a partner, and just lost both its major collaborators (AstraZeneca and Hansoh) within months of each other.
Silence Therapeutics plc is a UK-based clinical-stage biotechnology company developing siRNA (short interfering RNA) therapeutics that silence disease-associated genes in the liver using its proprietary mRNAi GOLD GalNAc-conjugated platform. The company generates revenue primarily through collaboration agreements (upfront payments, option fees, research milestones) with partners such as AstraZeneca and Hansoh, plus royalties, rather than product sales. It has never generated product revenue and operates at a net loss.
What the news says · bullish
The dominant storyline for SLN centers on positive clinical momentum, particularly durable Phase 1 data for divesiran in polycythemia vera and an upcoming August 2026 readout that analysts view as a catalyst. A Cantor Fitzgerald upgrade drove a sharp single-day rally on June 24, adding to a prior 19% surge in April, suggesting the stock has seen multiple re-rating events in 2026. Analysts are constructive on the zerlasiran program shift and divesiran's differentiated profile around fewer blood draws. However, lingering concerns about cash burn, revenue headwinds, and a February share price dive temper the enthusiasm, and the ATM ADS program launch signals ongoing dilution risk. Coverage is moderately active and skews bullish near-term, but fundamental risks remain material for this clinical-stage company.
This analysis is from Jun 25, 2026. Markets move. Get the current read on SLN and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.